Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

NCT01536366 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: BIA 9-1067
DRUG: Repaglinide

Sponsor

Bial - Portela C S.A.